INTRANASAL DEXMEDETOMIDINE PDF

Log in to view full text. If you're not a subscriber, you can:. Colleague's E-mail is Invalid. Your message has been successfully sent to your colleague.

Author:Jut Zolot
Country:Bahamas
Language:English (Spanish)
Genre:Medical
Published (Last):9 February 2012
Pages:75
PDF File Size:13.45 Mb
ePub File Size:6.63 Mb
ISBN:686-9-82695-544-9
Downloads:59193
Price:Free* [*Free Regsitration Required]
Uploader:Gardajind



Study record managers: refer to the Data Element Definitions if submitting registration or results information. Other Name: intranasal dexmedetomidine Placebo Comparator: placebo intranasal saline Drug: placebo 0. American Society of Anesthesiologists ASA status of patients receiving intranasal placebo or dexmedetomidine. ASA V: Moribund condition in a patient who is not expected to survive with or without the operation.

Anxiety score of Patients Receiving Intranasal dexmedetomidine at Pre-induction. Predicted effect-site concentrations of propofol after intranasal placebo at tracheal intubation. Propofol was infused intraoperatively to a target-controlled infusion TCI plasma concentration of 2. The infusion rate was adjusted via plasma concentration increments of 0. Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at tracheal intubation.

Propofol was infused intraoperatively to a TCI plasma concentration of 2. Predicted effect-site concentrations of propofol after intranasal placebo before inserting operative laryngoscope. Predicted effect-site concentrations of propofol after intranasal dexmedetomidine before inserting operative laryngoscope.

Predicted effect-site concentrations of propofol after intranasal placebo on removal of operative laryngoscope. Predicted effect-site concentrations of propofol after intranasal dexmedetomidine on removal of operative laryngoscope. Predicted effect-site concentrations of propofol after intranasal placebo at return of spontaneous breathing.

Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at return of spontaneous breathing. Predicted effect-site concentrations of propofol after intranasal placebo at emergence. Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at emergence.

Predicted effect-site concentrations of propofol after intranasal placebo at extubation. Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at extubation. Predicted effect-site concentrations of remifentanil after intranasal placebo at tracheal intubation. Remifentanil was infused to achieve a TCI plasma concentration of 3. To maintain a neuromuscular blockade, 0.

Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at tracheal intubation. Predicted effect-site concentrations of remifentanil after intranasal placebo before inserting operative laryngoscope. Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine before inserting operative laryngoscope. Predicted effect-site concentrations of remifentanil after intranasal placebo on removal of operative laryngoscope.

Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine on removal of operative laryngoscope. Predicted effect-site concentrations of remifentanil after intranasal placebo at return of spontaneous breathing.

Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at return of spontaneous breathing. Predicted effect-site concentrations of remifentanil after intranasal placebo at emergence. Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at emergence. Predicted effect-site concentrations of remifentanil after intranasal placebo at extubation. Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at extubation.

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.

For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms x. COVID is an emerging, rapidly evolving situation. Save this study. Warning You have reached the maximum number of saved studies Intranasal Dexmedetomidine Premedication The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Results First Posted : March 14, Last Update Posted : March 14, Study Description. Most patients with preoperative varying degrees of stress, anxiety, which makes the stress response in patients and affect the normal conduct of anesthesia and surgery. The sympathetic system hyperexcitability prone to cause adverse cardiovascular events and affect postoperative recovery.

However, phenobarbital, as the traditional premedication, has less sedative, weak anxiolytic and other shortcomings. Midazolam accompanied by inhibition of respiration,excessive sedation, easily induced delirium,prolonged recovery time and so on. Therefore, dexmedetomidine as premedication has certain advantages. The purpose of this research is to study sedative effect, safety and the impact of anesthesia recovery period of intranasal dexmedetomidine premedication for suspension laryngoscopy.

Detailed Description:. The study drug was prepared in a 1-ml syringe. An equal volume of dexmedetomidine or placebo was dropped into each nostril by a blinded research assistant in the supine position. Automatic sphygmomanometer measure blood pressure. Oxygen saturation and heart rate were measured by a pulse oximeter.

Respiratory rate, sedation score and anxiety levels regularly assessed. Patients with general anesthesia, suspension laryngoscopy surgery and postoperative care, standard monitoring are unified.

FDA Resources. Arms and Interventions. Outcome Measures. Heart rate HR of patients receiving intranasal placebo or dexmedetomidine. HR was monitored in the study. Baseline characteristic data of patients receiving intranasal dexmedetomidine The weights of 40 adult patients receiving intranasal dexmedetomidine. Baseline characteristic data of patients receiving intranasal placebo The heights of 41 adult patients receiving intranasal placebo.

Baseline characteristic data of patients receiving intranasal dexmedetomidine The heights of 40 adult patients receiving intranasal placebo. Baseline characteristics sex of patients receiving intranasal placebo or dexmedetomidine The sex of 81 adult patients receiving intranasal placebo or dexmedetomidine.

Duration from intranasal drug administration to arrival at operating room of patients receiving intranasal placebo surgical data of patients receiving intranasal placebo. Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal dexmedetomidine surgical data of patients receiving intranasal dexmedetomidine.

Duration from intranasal drug administration to anesthesia intubation of Patients Receiving Intranasal Placebo surgical data of patients receiving intranasal placebo. Duration of anesthesia of patients receiving intranasal placebo Duration from anesthesia intubation to anesthesia ending. Duration of anesthesia of patients receiving intranasal dexmedetomidine Duration from anesthesia intubation to anesthesia ending.

Duration of surgery of patients receiving intranasal placebo Duration from surgery beginning to anesthesia ending. Duration of surgery of patients receiving intranasal dexmedetomidine. Duration from surgery beginning to anesthesia ending. Satisfaction scores of patients receiving intranasal placebo. Satisfaction scores of patients receiving intranasal dexmedetomidine.

Time to spontaneous breathing of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and adequate ventilation. Time to spontaneous breathing of patients receiving intranasal dexmedetomidine. Time to consciousness of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and consciousness. Time to consciousness of patients receiving intranasal dexmedetomidine. Time to extubation of patients receiving intranasal placebo.

The time elapsed between stopping anesthetic infusions and extubation. Time to extubation of patients receiving intranasal dexmedetomidine. HR in the placebo group Before Intranasal Drugs HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room. HR in the dexmedetomidine group Before Intranasal Drugs. HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room. HR in the placebo group at pre-induction.

HR in the dexmedetomidine group at pre-induction. Patients with postoperative analgesia in two groups. An investigator who was blinded from the grouping asked the patients to mark their pain level on a visual analogue scale VAS.

A VAS higher than 50 was considered a worse outcome and need to be treated with intravenous 40 mg of parecoxib.

ACCOUNTING UNDERSTANDING AND PRACTICE PERKS AND LEIWY PDF

Intranasal Dexmedetomidine Premedication

Study record managers: refer to the Data Element Definitions if submitting registration or results information. Other Name: intranasal dexmedetomidine Placebo Comparator: placebo intranasal saline Drug: placebo 0. American Society of Anesthesiologists ASA status of patients receiving intranasal placebo or dexmedetomidine. ASA V: Moribund condition in a patient who is not expected to survive with or without the operation. Anxiety score of Patients Receiving Intranasal dexmedetomidine at Pre-induction. Predicted effect-site concentrations of propofol after intranasal placebo at tracheal intubation. Propofol was infused intraoperatively to a target-controlled infusion TCI plasma concentration of 2.

GLASS WALKERS TRIBEBOOK PDF

Intranasal Dexmedetomidine as a Sedative for Pediatric Procedural Sedation

Metrics details. Intranasal dexmedetomidine DEX , as a novel sedation method, has been used in many clinical examinations of infants and children. However, the safety and efficacy of this method for electroencephalography EEG in children is limited. In this study, we performed a large-scale clinical case analysis of patients who received this sedation method. The purpose of this study was to evaluate the safety and efficacy of intranasal DEX for sedation in children during EEG.

IMM 5553 PDF

Optimal Timing for the Administration of Intranasal Dexmedetomidine for Premedication in Children

Colleague's E-mail is Invalid. Your message has been successfully sent to your colleague. Save my selection. Funding: This work was supported by governmental research grant number from the Hospital District of South-West Finland, Finland. Supplemental digital content is available for this article.

HELIOTROPIUM CURASSAVICUM PDF

Register for a free account

This study seeks to evaluate the efficacy and safety of intranasal IN dexmedetomidine as a sedative medication for non-invasive procedural sedation. Subjects 6 months to 18 years of age undergoing non-invasive elective procedures were included. IN dexmedetomidine may be used for non-invasive pediatric procedural sedation. Also, patients sedated with IN dexmedetomidine had longer time to discharge, procedure time, and total admit time in comparison to other forms of sedation.

Related Articles